Toni Martinez

🧬 New Mutant p53 research report!

Highlight:

- TP53-mut diffuse follicular lymphoma with cnLOH at 1p36 highlights molecular profiling.

- Mut p53 rewires CXCL10, boosting CD8⁺ T cells and anti-PD-1 response.

@biomednews.bsky.social

biomed.news/bims-p53act/...

#p53 #CancerResearch

New Mutant p53 & Cancer Therapy Response Report is out! 🧬

Highlights:

• Lung-specific p53 mutants bind DNA but fail to transactivate

• Rezatapopt shows Phase I activity in Y220C tumors

@biomednews.bsky.social

#p53 #CancerResearch #Oncology

biomed.news/bims-p53act/...

New weekly Mutant p53 & Anti-Cancer Therapy Response report out now 🧬🧠

This issue highlights:

- Novel drug and prodrug candidates targeting TP53 mutations
- TP53-dependent cell fate in glioblastoma

@biomednews.bsky.social

biomed.news/bims-p53act/...

#p53 #Oncology #CancerResearch

New week, new report 🧬

My weekly Mutant p53 & anti-cancer therapy response report is out.

Fresh evidence on how TP53 mutations shape treatment response in cancer.

@biomednews.bsky.social

#p53 #Cancer #Oncology #CancerTherapy #BiomedsNews

biomed.news/bims-p53act/...

Pro‐ATO/Allicin Liposomes for Dual‐Pathway Targeting of p53‐Mutant Tumors Schematic illustration of the “pro-ATO”/allicin liposomal strategy. Liposomal encapsulation improves the stability and bioavailability of both agents while masking allicin's odor. Upon release in the....

Highlight:

"Pro-ATO/Allicin Liposomes for Dual-Pathway Targeting of p53-Mutant Tumors"

advanced.onlinelibrary.wiley.com/doi/10.1002/...

A new Biomeds News report is out 🚀

This week’s update on mutant p53 & anti-cancer therapy response - key papers, one place.

@biomednews.bsky.social

#p53 #CancerResearch #Oncology #BiomedsNews

biomed.news/bims-p53act/...

Nou article a #Docusalut: Hotspot mutant p53-R273H enhances mitochondrial biogenesis and cell migration in primary colorectal cancer in response to oxaliplatin  http://hdl.handle.net/20.500.13003/26209  @idisba.bsky.social  #PublicaSalutIB

Efficacy of melflufen in multiple myeloma with mutated or deleted TP53 - Experimental Hematology & Oncology Patients with multiple myeloma bearing a deletion of chromosome 17p (del(17p)), mutation of TP53, or both have poorer prognosis compared to patients without these aberrations. We investigated the acti...

Highlight:

"Efficacy of melflufen in multiple myeloma with mutated or deleted TP53"

link.springer.com/article/10.1...

Here we go again! Kicking off 2026 🚀, my weekly report about mutant p53 and anti-cancer therapy response is out.

@biomednews.bsky.social

#p53 #Oncology #CancerTherapy #BiomedsNews

biomed.news/bims-p53act/...

Multilayered Regulatory Dynamics of p53 Mutations and Platinum Resistance in Ovarian Cancer TP53 mutation-driven gene expression programs define oncogenic phenotypes. While extensive studies have concentrated on the transcriptome and proteome, post-transcriptional processes, particularly translational variation, remain underexplored. This study presents a comprehensive analysis of the transcriptomics, translatiomics, and proteomics dynamics in the ovarian cancer cell line SKOV3, with a focus on the effects of p53 missense mutations (R175H, R273H, and Y220C) on gene dosage fluctuations. Despite clear transcriptional differences between wild-type and mutant p53, we find that extensive translational and post-translational buffering processes attenuate these discrepancies, yielding comparatively stable protein abundances. Moreover, we delineate that the relative contributions of transcription output, translation engagement, and protein stability collectively shape the final protein abundance in the context of p53 mutations. Clinical proteomic analysis of platinum-resistant ovarian cancer tissues reveals tumor-specific factors and acquired resistance pathways linked to p53 mutations. Our findings elucidate the multilayered regulatory landscape of p53 mutations and identify potential risk factors for platinum resistance associated with these mutations.

Highlight:
pubs.acs.org/doi/10.1021/...

Just before Christmas🎄, my weekly Biomeds News report is out.

Growing evidence shows the clinical relevance of mutant p53 in treatment response, positioning it as a key axis in anticancer therapy.

@biomednews.bsky.social

#p53 #Oncology

biomed.news/bims-p53act/...

Merry Christmas!!!

Integrative Multi‐Omics Analysis Unveils the Molecular Mechanisms by Which TP53 Mutation Influence Early Decitabine Resistance in Myelodysplastic Syndrome The myelodysplastic syndrome (MDS) is group of clonal hematopoietic stem cell disorders typified by peripheral cytopenia, dysplastic hematopoietic progenitors, a hypercellular or hypocellular bone ma...

Highlight:

Integrative Multi-Omics Analysis Unveils the Molecular Mechanisms by Which TP53 Mutation Influence Early Decitabine Resistance in Myelodysplastic Syndrome

onlinelibrary.wiley.com/doi/10.1002/...

🧬Mutant p53 & anticancer therapy - weekly update.

A curated snapshot of recent studies on therapy response, resistance and tumour adaptation across cancers.

biomed.news/bims-p53act/...

@biomednews.bsky.social

#p53 #Oncology #CancerResearch

Taken together, these studies reinforce a clear signal:

TP53 mutations are increasingly being explored as context-dependent therapeutic vulnerabilities, not just prognostic markers.

#TargetedTherapy #DNADamage

🧬 Our latest @biomednews.bsky.social report on mutant #p53 and anticancer therapy is out.

Across multiple #Cancer types, recent studies highlight how TP53 #mutations intersect with tumor plasticity, DNA repair pathways, immune context and treatment response.

biomed.news/bims-p53act/...

#Oncology

Our new Biomed News issue on Mutant p53 & Anticancer Therapy is live - 9 fresh papers this week, spanning mechanisms, resistance, and new therapeutic angles.

Great selection for anyone following the p53 field!🔬

biomed.news/bims-p53act/...

@biomednews.bsky.social

#p53 #CancerResearch #Oncology

Distinct functional heterogeneity of TP53 R175 mutations in platinum-resistant ovarian cancer: unveiling molecular mechanisms and therapeutic targets - Cell Death & Disease Cell Death & Disease - Distinct functional heterogeneity of TP53 R175 mutations in platinum-resistant ovarian cancer: unveiling molecular mechanisms and therapeutic targets

Not all TP53 mutations are equal.

This study reveals that R175H and R175G variants in ovarian cancer differ in partners and pathways driving platinum resistance - with CHD1–IL7R emerging as mutation-specific therapeutic targets.

#OvarianCancer

www.nature.com/articles/s41...

Mutant p53 Regulates Pyruvate Dehydrogenase Kinase 1 (PDK1) to Promote Proliferation and Migration in Breast Cancer PDK1 is a direct transcriptional repression target of wtp53 and mutp53 can sustain its own stability by upregulating PDK1 in breast cancer.

Mutant p53 fuels breast cancer growth through a positive feedback loop with PDK1, boosting proliferation and migration.

Inhibiting PDK1 enhances the effect of APR-246, pointing to a promising combo therapy for TP53-mutant tumors.

#p53 #CancerMetabolism

onlinelibrary.wiley.com/doi/10.1111/...

🧬 New #BiomedNews report out in Mutant #p53 and anti-cancer therapies.

Two recent papers highlight how specific TP53 mutations drive tumor behavior and reveal new therapeutic vulnerabilities.

biomed.news/bims-p53act/...

@biomednews.bsky.social

Take a look at our new report from @tonimarber.bsky.social

Correlation between P53 immunohistochemical staining and TP53 molecular testing in endometrial carcinomas: a detailed assessment of discrepant cases with implications for patient management Our study demonstrates a good overall concordance between p53 immunohistochemical staining and TP53 molecular results in endometrial carcinomas. The concordance can be increased by reviewing the p53 ....

Featured paper: “Correlation between p53 IHC and TP53 testing in endometrial carcinomas”

🧬 Strong overall concordance, but a small group shows WT p53 staining despite TP53 mutations - key for diagnosis & treatment.

#p53 #oncology #mutations #diagnosis

🔗 doi.org/10.1111/his....

I’m excited to launch my first @biomednews.bsky.social report:
p53 mutations and anti-cancer therapy response

🧬 Starting small with 2 papers, more coming as ernad learns!
🚀 Exploring how mutant #p53 drives therapy adaptation.

biomed.news/bims-p53act/...
(And yes, my own recent paper’s included 👀)

Proud to see this story come to life after years of work!

If you’re interested in how mutant p53 rewires mitochondrial metabolism to shape tumor adaptation and chemoresistance, take a look 👇

doi.org/10.1016/j.bb...

#p53 #Mitochondria #ColorectalCancer #Oxaliplatin #Metabolism #CancerResearch

This work was a collaborative effort between @gmot16.bsky.social and colleagues from the University of Verona 🇮🇹, Prof. Massimo Donadelli and Dr. Alessandra Fiore. Huge thanks to @peremmb.bsky.social, @jordio2.bsky.social, @jordisastreserra.bsky.social, and @danielponsmiro.bsky.social!

We also observed that p53-R273H correlates with poor prognosis and metastatic behavior, promoting cell migration through vimentin upregulation - linking this mutation to EMT and enhanced invasive potential. 🧩

The primary CRC line showed diverse subpopulations under oxaliplatin, with some partially resistant, while the metastatic line responded uniformly - highlighting cell plasticity and tumor heterogeneity in treatment adaptation. 🔬

We found that p53 R273H triggers mitochondrial biogenesis via PGC1β and NRF1, driving a metabolic shift that boosts energy and cell migration in primary colorectal cancer - revealing how metabolism fuels tumor adaptation under chemo stress. ⚡

Hotspot mutant p53-R273H enhances mitochondrial biogenesis and cell migration in primary colorectal cancer in response to oxaliplatin Oxaliplatin is commonly known as a successful chemotherapy for advanced colorectal cancer, improving patient survival and eradicating micro-metastases…

Thrilled to share that the main paper from my PhD thesis is finally out!🧬

Our study shows how mutant p53 boosts mitochondrial biogenesis and cell migration under chemotherapy stress.

www.sciencedirect.com/science/arti...

@gmot16.bsky.social @uib.cat @iunics-uib.bsky.social @idisba.bsky.social

Torn del Dr. Toni Martínez @tonimarber.bsky.social per explicar la seva tesi doctoral realitzada al grup @gmot16.bsky.social

Foto de les persones que formen el grup GMOT

Avui acabam el curs acadèmic 2024-25, i volem compartir algunes de les fites més destacades del grup de recerca GMOT aquest any. Comencem!👇